Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

FDA warns three US firms over direct-to-consumer genetic testing

16 November 2015

By Lone Hørlyck

Appeared in BioNews 828

The US Food and Drug Administration (FDA) has sent warning letters to three gene-testing companies over the marketing and selling of what it claims are direct-to-consumer (DTC) gene-testing products without its approval.

The FDA said it was concerned about the potential public health consequences of test results.

Mr Eric Pahon, press officer at the FDA said that while the agency acknowledged that consumers are interested in information about genetic risks for disease, there were grounds for concern regarding the DTC tests.

'[The FDA] believes that certain types of tests are being appropriately offered through the DTC model, but others may need to demonstrate that they are safe and effective and that appropriate controls are in place to mitigate risks,' Pahon said.

The FDA said that the tests in question meet the criteria of a medical device and therefore require approval. Letters were sent to DNA4Life, DNA-cardioCheck and Interleukin Genetics and stated that the FDA does not hold an approval for the tests in question. The companies must either provide evidence that approval has been given, or explain why the tests should not be considered products requiring approval.

Both DNA4Life and Interleukin Genetics have said that they do not believe they needed FDA approval to sell the test. DNA4Life has also argued that its test is 'physician-integrated', meaning that patients are required to share test results with a physician. There is some concern, however, over how patients will interpret test results to make decisions about the drugs they are taking, reports Reuters.

The FDA has previously warned several companies about the marketing of DTC gene tests. Among these is the gene testing company 23andMe, which discontinued the marketing of its health-related DTC genetic testing service in 2013 after being ordered to do so by the FDA (see BioNews 733).

The company has recently relaunched revised tests with FDA approval that will show carrier data for 36 genetic diseases, as well as predisposition tests for trait and wellness characteristics (see BioNews 825).

However, previous reports offering indications of adverse drug reactions and risk for common disorders with a genetic component were discontinued due to lack of approval by the FDA. The agency said that that the test results had low reliability, that test results could lead to self-management of drugs and that the rates of false positives and false negatives were unknown.

SOURCES & REFERENCES
GenomeWeb | 09 November 2015
 
Reuters | 11 November 2015
 
Tech Times | 11 November 2015
 
Regulatory Affairs Professional Society | 09 November 2015
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

10 April 2017 - by Jamie Rickman 
The US Food and Drug Administration has approved the first genetic test to estimate an individual's risk of disease that can be sold directly to consumers...
31 October 2016 - by Kulraj Singh Bhangra 
Personal genomics company 23andMe has halted plans to develop next-generation sequencing technology, it has revealed ...
09 May 2016 - by Craig Macpherson 
The development of a portable DNA laboratory for professionals and enthusiasts raises questions about how regulations can possibly protect consumers in this rapidly developing field...
21 March 2016 - by Ryan Ross 
A recent study has suggested that genetic tests to assess the risk of diseases like diabetes and lung cancer do little to motivate people to change their behaviour...
15 February 2016 - by Kulraj Singh Bhangra 
US start-up company Sure Genomics has launched the first whole-genome testing service available directly to consumers, for a cost of $2500...

22 October 2015 - by Julianna Photopoulos 
Genetic testing company 23andMe is relaunching its direct-to-consumer genetic tests in the USA, after receiving approval from the US Food and Drug Administration...
05 May 2015 - by BioNews 
For the 800th issue of BioNews, we asked Anne Wojcicki eight questions about personal genomics company 23andMe...

20 January 2014 - by Cait McDonagh 
A biotechnology company that produces genetically customised nutritional supplements has settled charges of deceptive advertising with the US Federal Trade Commission (FTC) over claims that its products could treat a number of ailments and diseases...
02 December 2013 - by Ruth Saunders 
The US Food and Drug Administration has ordered 23andMe to 'immediately discontinue' its Personal Genome Service after failing to undergo proper agency approval for its marketing claims...
02 April 2012 - by Ruth Saunders 
Last week the Parliamentary Office of Science and Technology (POST) released a POST Note - a guide for MPs and other parliamentarians on science and technology issues - on consumer genetic testing...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation